438 related articles for article (PubMed ID: 32293641)
1. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
Haynes D; Strunck JL; Topham CA; Ortega-Loayza AG; Kent G; Cassidy PB; Hu R; Choate K; Wang Z; Liu Y; Greiling TM
JAMA Dermatol; 2020 Jun; 156(6):668-675. PubMed ID: 32293641
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial.
Velasco RC; Shao C; Cutler B; Strunck J; Kent G; Cassidy PB; Choate K; Greiling TM
JAMA Dermatol; 2024 Jun; 160(6):641-645. PubMed ID: 38598229
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Boudreaux BW; Pincelli TP; Bhullar PK; Patel MH; Brumfiel CM; Li X; Heckman MG; Pittelkow MR; Mangold AR; Sluzevich JC
Br J Dermatol; 2022 Nov; 187(5):650-658. PubMed ID: 35701384
[TBL] [Abstract][Full Text] [Related]
4. Clinical response to ustekinumab in familial pityriasis rubra pilaris caused by a novel mutation in CARD14.
Eytan O; Sarig O; Sprecher E; van Steensel MA
Br J Dermatol; 2014 Aug; 171(2):420-2. PubMed ID: 24641799
[No Abstract] [Full Text] [Related]
5. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.
Craiglow BG; Boyden LM; Hu R; Virtanen M; Su J; Rodriguez G; McCarthy C; Luna P; Larralde M; Humphrey S; Holland KE; Hogeling M; Hidalgo-Matlock B; Ferrari B; Fernandez-Faith E; Drolet B; Cordoro KM; Bowcock AM; Antaya RJ; Ashack K; Ashack RJ; Lifton RP; Milstone LM; Paller AS; Choate KA
J Am Acad Dermatol; 2018 Sep; 79(3):487-494. PubMed ID: 29477734
[TBL] [Abstract][Full Text] [Related]
6. CARD14 Glu138 mutation in familial pityriasis rubra pilaris does not warrant differentiation from familial psoriasis.
Inoue N; Dainichi T; Fujisawa A; Nakano H; Sawamura D; Kabashima K
J Dermatol; 2016 Feb; 43(2):187-9. PubMed ID: 26130407
[TBL] [Abstract][Full Text] [Related]
7. Identification of a pathogenic
Nielsen RM; Gram SB; Bygum A
BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33431438
[TBL] [Abstract][Full Text] [Related]
8. Histopathologic findings characteristic of CARD14-associated papulosquamous eruption.
Ring NG; Craiglow BG; Panse G; Antaya RJ; Ashack K; Ashack R; Faith EF; Paller AS; McNiff JM; Choate KA; Ko CJ
J Cutan Pathol; 2020 May; 47(5):425-430. PubMed ID: 31849081
[TBL] [Abstract][Full Text] [Related]
9. Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations.
Takeichi T; Sugiura K; Nomura T; Sakamoto T; Ogawa Y; Oiso N; Futei Y; Fujisaki A; Koizumi A; Aoyama Y; Nakajima K; Hatano Y; Hayashi K; Ishida-Yamamoto A; Fujiwara S; Sano S; Iwatsuki K; Kawada A; Suga Y; Shimizu H; McGrath JA; Akiyama M
JAMA Dermatol; 2017 Jan; 153(1):66-70. PubMed ID: 27760266
[TBL] [Abstract][Full Text] [Related]
10. Clinical response of CARD14-associated papulosquamous eruption to an anti-interleukin-17A antibody.
Klein B; Treudler R; Dumann K; Boldt A; Schumann I; Simon JC; Kunz M
Br J Dermatol; 2022 Sep; 187(3):419-422. PubMed ID: 35262907
[TBL] [Abstract][Full Text] [Related]
11. CARD14-mutations in pityriasis rubra pilaris and therapeutic response to ustekinumab - a hypothesis.
Volc-Platzer B
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1312-1315. PubMed ID: 32881385
[No Abstract] [Full Text] [Related]
12. Beneficial effect of ustekinumab in familial pityriasis rubra pilaris with a new missense mutation in CARD14.
Lwin SM; Hsu CK; Liu L; Huang HY; Levell NJ; McGrath JA
Br J Dermatol; 2018 Apr; 178(4):969-972. PubMed ID: 28301045
[TBL] [Abstract][Full Text] [Related]
13. The management and genetic background of pityriasis rubra pilaris: a single-centre experience.
Gál B; Göblös A; Danis J; Farkas K; Sulák A; Varga E; Nagy N; Széll M; Kemény L; Bata-Csörgő Z
J Eur Acad Dermatol Venereol; 2019 May; 33(5):944-949. PubMed ID: 30697821
[TBL] [Abstract][Full Text] [Related]
14. Analysis of CARD14 Polymorphisms in Pityriasis Rubra Pilaris: Activation of NF-κB.
Li Q; Jin Chung H; Ross N; Keller M; Andrews J; Kingman J; Sarig O; Fuchs-Telem D; Sprecher E; Uitto J
J Invest Dermatol; 2015 Jul; 135(7):1905-1908. PubMed ID: 25734815
[No Abstract] [Full Text] [Related]
15. The beneficial effect of a PDE4 inhibitor in a patient with juvenile-onset intractable pityriasis rubra pilaris without CARD14 mutation.
Inoue E; Arase N; Hanaoka Y; Tanemura A; Fujimoto M
Dermatol Ther; 2021 Jan; 34(1):e14714. PubMed ID: 33368948
[No Abstract] [Full Text] [Related]
16. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
Feldmeyer L; Mylonas A; Demaria O; Mennella A; Yawalkar N; Laffitte E; Hohl D; Gilliet M; Conrad C
JAMA Dermatol; 2017 Apr; 153(4):304-308. PubMed ID: 28122069
[TBL] [Abstract][Full Text] [Related]
17. [Pityriasis rubra pilaris : Successful treatment with ixekizumab].
Kohn D; Wetzig T
Hautarzt; 2020 Aug; 71(8):624-626. PubMed ID: 32185430
[TBL] [Abstract][Full Text] [Related]
18. A novel mutation in a CARD14-associated papulosquamous eruption.
Li N; Tao J; Zhang J; Liu Z; Yu P
Pediatr Dermatol; 2023; 40(4):706-709. PubMed ID: 36724903
[TBL] [Abstract][Full Text] [Related]
19. CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature.
Frare CP; Blumstein AJ; Paller AS; Pieretti L; Choate KA; Bowcock AM; Larralde M
Pediatr Dermatol; 2021 Sep; 38(5):1237-1242. PubMed ID: 34448248
[TBL] [Abstract][Full Text] [Related]
20. Familial pityriasis rubra pilaris in a Chinese family caused by a novel mutation in CARD14 gene.
Wu T; Banerjee S; Deng J; Wu J; Huang H; Zheng H; Pan H; Wang Y; Peng Z; Sun X
Indian J Dermatol Venereol Leprol; 2020; 86(1):81-84. PubMed ID: 31755479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
